Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. on Positive Outlook

Share:
Related MRK
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
Adam Feuerstein Talks Vulnerable Pharmaceuticals, Drug Pricing Under Trump
Stocks Move To Highs; Amazon Breaks Out On 'Buy' Rating (Investor's Business Daily)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Merck & Co. (NYSE: MRK), and raised the price target from $46.00 to $48.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Merck & Co. closed on Tuesday at $45.51.

Latest Ratings for MRK

DateFirmActionFromTo
Jan 2017GuggenheimUpgradesNeutralBuy
Jan 2017Morgan StanleyUpgradesEqual-WeightOverweight
Dec 2016JefferiesDowngradesHoldUnderperform

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!